| abstract |
The invention relates to crystalline anhydrous forms, crystalline solvate forms and / or salt forms, including crystalline salt forms of {(S) -3- [6- (6-methoxy-5-methyl - pyridin-3-yl) -5,6,7,8-tetrahydro-piri do- [4,3-d] -pyrimidin-4-yloxy] -pyrrolidin-1-yl} - (tetrahydro-pyran- 4- il) -methanone, or to the salt forms, including the crystalline salt forms of 1 - {(S) -3- [6- (6- methoxy-5-trifluoro-methyl-p iridin-3-yl) - 5,6,7,8-tetrahydro-pyrido- [4,3-d] -pyrimidin-4-yl-ami no] -pyrrolidin-1-yl} -propan-1-one; to pharmaceutical compositions and combinations that include these forms, as well as to the methods for using these forms, including their pharmaceutical compositions and combinations for the treatment of diseases. |